Publications

• A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV
  SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., Alves, J., … Pingoud, A. (1992). A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV. BIOCHEMISTRY, 31(20), 4808–4815.
• Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
  Liedtke, M., Hamlin, P. A., Moskowitz, C. H., & Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. ANNALS OF ONCOLOGY, 17(6), 909–913.
• Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
  Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581–85.
• 
  
• 
  
• 
  
• 
  
• Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37.
  
• Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901.
  
• Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325–31.
  
• The Transcription Factor Encyclopedia Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., Cheung, W. A., … Wasserman, W. W. (2012). The Transcription Factor Encyclopedia. GENOME BIOLOGY, 13(3).
  
• 
  
• 
  
• Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Hematology (Amsterdam, Netherlands).
  
• Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96.
  
• Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Kumar, R. (2013). Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 11–17.
  
• 
  
• The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., … Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367–72.
  
• Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., … Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98(10), 1593–99.
  
• AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., … Alhamadsheh, M. M. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(24), 9992–97.
  
• Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. ONCOGENE, 17(15), 1889–1892.
  
• Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).
  
• Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2011). Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy. JOURNAL OF CARDIAC FAILURE, 17(8), S45–S46.
  
• Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., … Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158–62.
  
• Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., Natkunam, Y., & Warnke, R. A. (2014). Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. American Journal of Surgical Pathology, 38(9), 1298–1304.
  
• Effects of serum and plasma matrices on multiplex immunoassays. Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., & Maecker, H. T. (2014). Effects of serum and plasma matrices on multiplex immunoassays. Immunologic Research, 58(2-3), 224–33.
  
• Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia Dinner, S., Lee, D., & Liedtke, M. (2014). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(8), 1715–24.
  
• Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45.
  
• Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., … Witteles, R. M. (2015). Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. American Journal of Transplantation , 15(3), 650–58.
  
• 
  
• Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma Hansmann, L., Blum, L., Ju, C.-H., Liedtke, M., Robinson, W. H., & Davis, M. M. (2015). Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma. CANCER IMMUNOLOGY RESEARCH, 3(6), 650–60.
  
• 
  
• Multiple Myeloma, Version 2.2016 Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2015). Multiple Myeloma, Version 2.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1398–1435.
  
• A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59.
  
• First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., Zonder, J., … Liedtke, M. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology , 34(10), 1097–1103.
  
• Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. Leatham, H. W., Novoa, R., Liedtke, M., & Kwong, B. Y. (2016). Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. Clinical Lymphoma, Myeloma & Leukemia, 16(1), e1–5.
  
• 
  
• Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., … Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740–53.
  
• Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2016). Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(4), 389–400.
  
• Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., … Kumar, R. (2017). Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(2), 230-?
  
• Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia.
  
• 
  
• 
  
• NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY Liedtke, M., Comenzo, R., Landau, H., Sanchorawala, V., Weiss, B., Zonder, J., … Gertz, M. (2017). NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(11), 825.
  
• NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response Liedtke, M. M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response. EUROPEAN JOURNAL OF HEART FAILURE, 19, 441.
  
• A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis Cohen, A. D., Scott, E. C., Liedtke, M., Kaufman, J. L., Landau, H., Vesole, D. H., … Durie, B. G. M. (2014). A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. BLOOD, 124(21).
  
• Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016 Maurer, M., Lousada, I., Hanna, M., Ruberg, F., Mohty, D., Dispenzieri, A., … Grogan, M. (2017). Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 24, 165–66.
  
• Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2015). Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. BLOOD, 126(23).
  
• The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. Liedtke, M., Merlini, G., Landau, H. J., Comenzo, R., Seldin, D. C., Weiss, B. M., … Gertz, M. A. (2015). The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2016). NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study. EUROPEAN HEART JOURNAL, 37, 220.
  
• 
  
• NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., … Shead, D. A. (2018). NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(1), 11–20.
  
• 
  
• NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response. ONCOLOGY RESEARCH AND TREATMENT, 40, 34–35.
  
• NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY Gertz, M., Comenzo, R. L., Landau, H., Sanchorawala, Weiss, B. M., Zonder, J. A., … Liedtke, M. (2017). NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 22(3), 289–90.
  
• Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE Jabbour, E. J., DeAngelo, D. J., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2018). Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE. CANCER, 124(8), 1722–32.
  
• Novel therapeutic approaches for AL amyloid Liedtke, M. (2017). Novel therapeutic approaches for AL amyloid. ONCOLOGY RESEARCH AND TREATMENT, 40, 194.
  
• Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., … Advani, A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. BLOOD ADVANCES, 1(15), 1167–80.
  
• Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. BLOOD, 130(7), 900–902.
  
• Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., … Advani, A. S. (2018). Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. LEUKEMIA & LYMPHOMA, 59(2), 363–71.
  
• A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology.
  
• Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., & Dunn, T. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. Journal of Adolescent and Young Adult Oncology.
  
• Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma Richardson, P. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., … Baz, R. (2018). Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 182(2), 231–44.
  
• 
  
• Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis Yen, T., Chen, F., Witteles, R., Liedtke, M., & Nguyen, L. A. (2017). Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112, S240.
  
• 
  
• 
  
• Grading cardiac response in AL amyloidosis: implications for relapse and survival. Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2018). Grading cardiac response in AL amyloidosis: implications for relapse and survival. British Journal of Haematology.
  
• Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Jabbour, E., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2019). Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology.
  
• 
  
• Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse Aleshin, A., Durruthy-Durruthy, R., Corces, M. R., Stafford, M., Liedtke, M., Medeiros, B. C., … Majeti, R. (2018). Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse. BLOOD, 132.
  
• Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia.
  
• Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., … Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer.
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• Grading cardiac response in AL amyloidosis: implications for relapse and survival Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2019). Grading cardiac response in AL amyloidosis: implications for relapse and survival. BRITISH JOURNAL OF HAEMATOLOGY, 186(1), 144–46.
  
• 
  
• 
  
• 
  
• A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. Barrett, C. D., Dobos, K., Liedtke, M., Tuzovic, M., Haddad, F., Kobayashi, Y., … Witteles, R. M. (2019). A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. JACC. Heart Failure.
  
• 
  
• 
  
• 
  
• 
  
• Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Jabbour, E., Gokbuget, N., Advani, A., Stelljes, M., Stock, W., Liedtke, M., … Kantarjian, H. (2019). Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research, 88, 106283.
  
• Cutaneous plasmablastic plasmacytoma. Chung, A., & Liedtke, M. (2019). Cutaneous plasmablastic plasmacytoma. Blood, 134(23), 2116.